



**Dr. Alan Lazarus**

*Keenan Research Centre of the Li Ka Shing  
Knowledge Institute of St. Michael's Hospital*

Wednesday, Nov 16, 2011  
12:00pm  
in LSC3

Life Sciences Centre  
2350 Health Sciences Mall

## “How does IVIg work in autoimmunity and can we replace it with something better?”

Intravenous immunoglobulin (IVIg) is used to treat autoimmune diseases, such as immune thrombocytopenia (ITP). IVIg is a limited resource, and its dosage and cost are both high. Although considered safe, it is a pooled plasma-derived blood product and will always carry a theoretical risk of transferring infectious disease. Thus, it would be highly desirable to improve the efficacy of IVIg or develop monoclonal antibodies capable of mimicking the clinical effects of IVIg. To explore the potential for monoclonal antibodies as a treatment for autoimmunity, we tested a spectrum of antibodies and found that several antibodies specific for the CD44 homing antigen were effective in ITP and arthritis. The results and implications of this work will be discussed.

This Seminar is sponsored by:

# CSL Behring

Host: Dr. Ed Prydzial, Clinical Professor Pathology and Laboratory Medicine & Centre for Blood Research



Refreshments will be served 10 minutes before the seminar  
Seminar information: 604 822 7407

